1st drug for rare rapid-aging disease extends kids' lives

News

1st drug for rare rapid-aging disease extends kids' lives

In this Feb. 12, 2019 photo, Meghan Waldron walks down the street in Boston. Waldron is a freshman at Emerson College with progeria, one of the world's rarest diseases. The first treatment has been approved for progeria, Friday, Nov. 20, 2020. The U.S. Food and Drug Administration on Friday approved Zokinvy which was shown in testing to extend patients’ lives by 2 ½ years on average. (Suzanne Kreiter/The Boston Globe via AP)
This photo provided by Eiger BioPharmaceuticals shows the pharmaceutical drug Zokinvy. The first treatment has been approved for progeria, an extremely rare genetic disorder that causes rapid aging, stunts growth and typically kills children in their early teens. The U.S. Food and Drug Administration on Friday, Nov. 20, 2020 approved. Zokinvy (Eiger BioPharmaceuticals via AP)

1st drug for rare rapid-aging disease extends kids' lives

In this Feb. 12, 2019 photo, Meghan Waldron walks down the street in Boston. Waldron is a freshman at Emerson College with progeria, one of the world's rarest diseases. The first treatment has been approved for progeria, Friday, Nov. 20, 2020. The U.S. Food and Drug Administration on Friday approved Zokinvy which was shown in testing to extend patients’ lives by 2 ½ years on average. (Suzanne Kreiter/The Boston Globe via AP)
This photo provided by Eiger BioPharmaceuticals shows the pharmaceutical drug Zokinvy. The first treatment has been approved for progeria, an extremely rare genetic disorder that causes rapid aging, stunts growth and typically kills children in their early teens. The U.S. Food and Drug Administration on Friday, Nov. 20, 2020 approved. Zokinvy (Eiger BioPharmaceuticals via AP)
click here to add your event
Area Events